Form 4: Whitehawk Therapeutics Director Receives Stock Options

Director Behzad Aghazadeh and associated entities reported the acquisition of 38,040 stock options in Whitehawk Therapeutics.

Summary

• Behzad Aghazadeh, representing Avoro Capital Advisors LLC and Avoro Ventures LLC, was granted 38,040 stock options in Whitehawk Therapeutics, Inc. (WHWK).
• The options have an exercise price of $4.16 per share.
• The grant date is June 12, 2026, with an expiration date of June 12, 2036.
• The options vest 100% on the earlier of the one-year anniversary of the grant or the day before the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of interests between a major shareholder/director and the company through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is contingent upon the reporting person continuing to serve as a Service Provider to the issuer.

Future Outlook

The options vest in full after one year or upon the next annual meeting, indicating a long-term retention incentive for the director.

Management Comments

• The reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.
• Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization due to Dr. Aghazadeh's board seat.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practice in the biotechnology sector to align board incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The use of 1-year cliff vesting for director options is consistent with standard equity incentive plans for small-cap biotech firms.
• The reporting structure involving 'director by deputization' is a common legal framework for venture capital firms holding board seats.

Corporate Governance

Related Party Transactions

• The filing involves Avoro Capital Advisors LLC and Avoro Ventures LLC, entities controlled by director Behzad Aghazadeh.

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of options on June 12, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Form 4, Insider Trading, Stock Options, Avoro Capital Advisors